English | 中文版 | 手机版 企业登录 | 个人登录 | 邮件订阅
当前位置 > 首页 > 行业资讯 > 展会 > VIF World 2025第6届疫苗创新国际论坛通知

VIF World 2025第6届疫苗创新国际论坛通知

浏览次数:2600 发布日期:2024-9-19  来源:本站 本站原创,转载请注明出处
Vaccine Innovation Forum(VIF) World 2025
第6届疫苗创新国际论坛



 2025年3月20-22日 | 中国 上海

120+演讲嘉宾
1000+参会代表
60+展商
30+国家和地区

持续推动中国与国际疫苗科学、市场的交流及合作

科学顾问委员会:
Bin Wang,艾棣维欣CSO /复旦大学教授
George Fu Gao, 中科院院士,教授
David Weiner,Wistar研究所执行副总裁;美国宾夕法尼亚大学名誉教授
Chunlin Xin,康希诺生物副总裁,
Yuanqing Liu,嘉晨西海中国CSO
Heinrich Haas,英国NeoVac CTO,
Alain Bouckenooghe,Hilleman Laboratories CSO
Shaowei Li,厦门大学教授
Amine Kamen,加拿大麦吉尔大学教授
Kiat Ruxrungtham,泰国朱拉隆功大学Chula疫苗研究中心主任
Dexiang Chen,迈科康生物董事长兼总经理
Anna Du,比尔及梅琳达盖茨基金会中国国家办事处高级项目官员
Li Shi,怡道生物董事长
Sean Du,赛诺菲巴斯德全球研发部亚太地区外部研发部负责人
Yuan Yuan,PATH中国国家代表,业务和联盟管理负责人
Petro Terblanche,南非Afrigen Biologics CEO
Linqi Zhang,清华大学教授
Xiaofeng Liang,中华预防医学会副会长,暨南大学教授
Yuelong Shu, 中国医学研究院病原生物学研究所所长
Diana Baraschi,意大利国家研究委员会院士,中国科学院深圳先进技术研究院特聘教授
Emanuele Montomoli, 意大利Siena大学教授/VisMederi创始人&首席科学家
Joon Haeng Rhee,韩国全南国立大学医学院教授
Michel De Wilde,前赛诺菲巴斯德研发部SVP
George Siber,Siber Biotechnologies总裁,约翰霍普金斯大学终身教授
Raman Rao, 新加坡Hilleman Laboratories CEO
Meng Li, 中国生物国际合作部主任
Ruben Rizzi, BioNTech全球法规事务高级副总裁
Huichen Guo, 兰州兽医研究所研究员
Ken Ishii,日本国际疫苗设计中心主任,东京大学教授

往届回顾:

 

 
 
主要话题:
创新疫苗开发进展
新疫苗平台和技术
基于RNA技术的疫苗及疗法
动物疫苗
癌症疫苗与免疫疗法
生物工艺和制造
临床试验与疫苗安全性
市场准入、监管和国际合作
佐剂、制剂和递送技术
全球健康与疾病防控

80+早期确认嘉宾:

Rajinder Suri, CEO, DCVMN International, Switzerland
Raches Ella, Chief Development Officer, Bharat Biotech, India
Hun Kim, President of Global Biz, SK bioscience, South Korea
Mahesh Kumar, SVP of R&D, Global Biologics, Zoetis, USA
Simon Graham, Professor, The Pirbright Institute, UK
Jidong Cui, Unit Head, Local Production & Assistance Unit, Innovation and Emerging Technologies Department
(IET),MHP, World Health Organization, Switzerland
Emanuel Montomoli, Professor, Full Prof. of Public Health, University of Siena;CSO of VisMederi Italy
George Siber, President, Siber Biotechnologies LLC, USA
Joon Haeng Rhee, Professor, Chonnam National University Medical School, South Korea
Diana Boraschi, Distinguished Professor, Shenzhen Institute of Advanced Technology, China
Melanie Saville, CSO, PATH, USA
Ken Ishii, Director, International Vaccine Design Center, Professor, University of Tokyo, Japan
Nikolai Petrovsky, Founder, Vaxine, Australia
Adrian V. S. Hill, Director, The Jenner Institute, Lakshmi Mittal & Family Professor of Vaccinology, University of Oxford , UK
Ruben Rizzi, Senior Vice President Global Regulatory Affairs,BioNTech, Germany
Raman Rao, CEO, the Hilleman Laboratories, Singapore
Meng Li, Director of International Cooperation, China National Biotec Group, China
Bin Wang, Professor, Fudan University/CSO, Advaccine, China
Linqi Zhang, Professor, Tsinghua University, China
Shaowei Li, Professor, Xiamen University, China
Nigel Temperton, Professor, Director, Viral Pseudotype Unit, University of Kent, UK
Kiat Ruxrungtham, Professor of Medicine, Director of Chula VRC, Chulalongkorn University, Thailand
Xiaofeng Liang, VP, Chinese Preventive Medicine Association; Professor, Jinan University, China
Tongqing Zhou, Chief, Structural Bioinformatics Section National Institutes of Health, USA
Shibo Jiang, Professor, Fudan University, China
Wei Tan, SVP, Head of China Research and External Collaboration, Clover Biopharmaceutical, China
Huichen Guo, Professor, Lanzhou Veterinary Research Institute, China
Baik-Lin Seong, Director General, Vaccine Innovative Technogy ALliance (VITAL)-Korea, South Korea
Christopher Netherton, Professor, The Pirbright Institute, UK
Nibal Dahaba, Co-Founder & General manager Emerging markets,Gennecs Holding, Egypt
Jiguo (Jeffrey) Zhang, President, Vaccine Division, Fosun Pharma, China
Petro Terblanche, CEO, Afrigen Biologics, South Africa
Zhaohua (Jessie) Chen, Head of Development China, General Manager of Pfizer China R&D, China
Yuelong Shu, Director, Institute of Pathogen Biology, CAMS & PUMC, China
Robbert van der Most, Former VP, Translational Science Infectious Diseases, BioNTech, CEO, VaxxCellence,Belgium
Jingxin Li, Vice Director of the Department, Jiangsu CDC, China
George Fu Gao, Former Director, China CDC; Academician, Professor, Chinese Academy of Sciences, China
Linfa Wang, Professor, Duke-NUS Medical School, Singapore
Dan Barouch, Professor, Harvard Medical School, USA
Nicaise Ndembi, Head for Partnerships for African Vaccine Manufacturing (PAVM) & Head Science Office, Africa CDC, Ethiopia
Yunlong Richard Cao, Assistant Professor, Peking University, China
Amine Kamen, Professor, McGill University, Canada
Lianpan Dai, Professor, Institute of Microbiology, Chinese Academy of Sciences, China
Han Wang, Associate Professor, Peking University, China
Patrícia Neves, Project Manager, mRNA center,Bio-Manguinhos/ Fiocruz, Brazil
Adel Sattarova, Head of Project activity department, FSUE SPbSRIVS FMBA of Russia
SeyedReza Banihashemi, Director of R&D,Razi Vaccine & Serum Research Institute, Iran
Pardi Norbert, Assistant Professor, Assistant Professor, University of Pennsylvania, USA
Kate Broaderick, Cheif Innovation Officer, Maravai Life Science
Hani Kim, Executive Director, RIGHT Foundation, South Korea
Jian Dong, CEO, WuXi Vaccines; SVP, WuXi Biologics, China
Qihan Li, Professor, Weirui Bio, China
Sean Du, Head, External R&D APAC, Global R&D, Sanofi Pasteur, China
Heinrich Hass, CTO, NeoVac, UK
Kate Broaderick, Chief Innovation Officer, Maravai Life Sciences, USA
Landian Hu, CEO, Anda Biology Medicine Development (Shenzhen)
Adham Rezk, CEO, Celero, Singapore 
Hong Jin, CSO, CyanVac, USA
Nguyen Tuyet Nga, South East Asia Hub Director/Vietnam Country Director, PATH, Vietnam
Peter L. Andersen, Chief Scientific Advisor, Infectious Diseases,Novo Nordisk Foundation, Denmark
Xiangrong Song, Cofounder& CEO, Westgene, China
Jie Li, Head of R&D, The Spirit Jinyu Biological Pharmaceutical, China
SuthiraTaychakhoonavudh,CEO,Baiya Phytopharm, Thailand
Dexiang Chen, CEO, Maxvax, China
Deog-Young Choi, CEO, InThera, South Korea
Yelin Xiong, VP, Yither Biotech, China
Francesca Ceddia, Chief Medical Affairs Officer, Moderna, USA
Zihao Wang, CEO, Immorna Bio, China
Francesco Berlanda Scorza, VP, R&D, Global Health R&D Vaccines Head and GVGH Institute Director, GSK, Italy
Bo Ying, Co-founder, Chairman&CEO, Abogen Biosciences, China
Peter Dull, Deputy Director at Bill & Melinda Gates Foundation, USA
Jiangsheng Xu, Co-founder&CSO, General Therapeutics, USA
Emanuele Andreano, Project Leader, Fondazione Toscana Life Sciences,
Italy
Hao Chen, AVP, Head of Vaccines & Advanced Biotechnologies Process R&D, Merck, USA
Hao Li, Associate Professor, China Agricultural University, China
Xuexiang Han, Professor, SIBCB, China
 
更多嘉宾正在赶来,不容错过!


 
详情请至会议官网:

 
联系主办方:
Sam Li
13482341046 (微信)
Sam.li@chstone-events.com
ChStone Events
上海崎石商务咨询有限公司
https://www.bagevent.com/event/8864845


用户名: 密码: 匿名 快速注册 忘记密码
评论只代表网友观点,不代表本站观点。 请输入验证码: 8795
Copyright(C) 1998-2024 生物器材网 电话:021-64166852;13621656896 E-mail:info@bio-equip.com